AsianScientist (Jun. 10, 2016) – German biopharmaceutical supplier Sartorius Stedim Biotech and Chinese pharmaceutical contract service provider WuXi Biologics have opened a joint laboratory in Shanghai to facilitate pilot studies and manufacture of novel biologics.
The laboratory is equipped with systems used by biopharmaceutical companies for early stage R&D and process optimization, and supports accelerated development, optimization and rapid scale-up of cell culture processes.
“As the upstream leader and pharmaceutical companies’ partner, Sartorius will strongly support the rapid expansion of the Chinese biopharmaceutical industry through speed to clinic, increased titers, quality by design, and robust production,” said Dr. Joerg Lindenblatt, senior vice president for Asia at Sartorius Stedim Biotech.
“WuXi Biologics is devoted to building the leading one-stop service platforms for biologics R&D and manufacture and to providing comprehensive services for biopharmaceutical clients throughout the world,” said Dr. Chris Chen, CEO of WuXi Biologics.
———
Source: Sartorius Stedim Biotech.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
